莫索尼定结构式
|
常用名 | 莫索尼定 | 英文名 | Moxonidine |
---|---|---|---|---|
CAS号 | 75438-57-2 | 分子量 | 241.678 | |
密度 | 1.5±0.1 g/cm3 | 沸点 | 364.7±52.0 °C at 760 mmHg | |
分子式 | C9H12ClN5O | 熔点 | 40-43 °C(lit.) | |
MSDS | 美版 | 闪点 | 174.3±30.7 °C |
莫索尼定用途Moxonidine(BDF5895)是咪唑啉1型受体(I1-R)选择性激动剂,为降压剂。 |
中文名 | 莫索尼啶 |
---|---|
英文名 | 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine |
中文别名 | 莫索尼定,不带盐酸 | 4-氯-N-(4,5-二氢-1H-咪唑-2-基)-6-甲氧基-2-甲基-5-嘧啶胺 | 莫索尼定 |
英文别名 | 更多 |
描述 | Moxonidine(BDF5895)是咪唑啉1型受体(I1-R)选择性激动剂,为降压剂。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.5±0.1 g/cm3 |
---|---|
沸点 | 364.7±52.0 °C at 760 mmHg |
熔点 | 40-43 °C(lit.) |
分子式 | C9H12ClN5O |
分子量 | 241.678 |
闪点 | 174.3±30.7 °C |
精确质量 | 241.073044 |
PSA | 71.43000 |
LogP | 0.84 |
外观性状 | 晶体 |
蒸汽压 | 0.0±0.8 mmHg at 25°C |
折射率 | 1.681 |
储存条件 | Desiccate at +4°C |
计算化学 | 1.疏水参数计算参考值(XlogP):0.6 2.氢键供体数量:2 3.氢键受体数量:4 4.可旋转化学键数量:3 5.互变异构体数量:2 6.拓扑分子极性表面积71.4 7.重原子数量:16 8.表面电荷:0 9.复杂度:275 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 | 1.性状:结晶 2.熔点(ºC):217-219℃(分解)。 |
危害码 (欧洲) | Xn |
---|---|
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | UV6260290 |
危险类别 | 6.1 |
方法1:5-氨基-4,6-二氯-2-甲基嘧啶和1-乙酰基-2-咪唑啉-2-酮反应,生成的产物和甲醇钠作用得莫索尼定。
方法2:5-氨基-4-氯-6-甲氧基-2-甲基嘧啶和硫氰酸铵及苯甲酰氯反应,得(I)。去苯甲酰基得(Ⅱ),甲基化得(Ⅲ),再和乙二胺作用得莫索尼定。
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
Curr. Med. Res. Opin. 20(3) , 359-67, (2004) Hypertension in combination with clinically overt diabetes mellitus is recognized as a particularly powerful combination of risk factors that greatly increases cardiovascular vulnerability. There is a... |
|
Moxonidine: a review of safety and tolerability after seven years of clinical experience.
J. Hypertens. 17 , S37-S39, (1999) Centrally acting antihypertensive drugs, or sympatholytics, (reserpine, methyldopa and clonidine) have a long history of efficacy but are now little used in most countries. One of the most important r... |
|
[The efficacy of antihypertension drugs and their combinations in the non-treated hypertension].
Med. Tr. Prom. Ekol. (5) , 7-11, (2013) In case of non-treated hypertension several medications and their combinations were studied (captopril, and moxonidine as such, captopril + nifedipine, captopril + moxonidine). Moxonidine to be more e... |
4-chloro-5-(imidazoline-2-ylamino)-6-methoxy-2-methylpyrimidine |
[3H]-Moxonidine |
4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine |
4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
Norcynt |
4-Chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine |
BE 5895 |
5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- |
Normoxocin |
Lomox |
4-chloro-N-(4,5-dihydro-1H9imidazol-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
Physiotens |
[14C]-Moxonidine |
4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methylpyrimidine |
T6N CNJ B1 DO1 FG EM- BT5M CN BUTJ |
Nucynt |
Cynt |
Moxonidinum [Latin] |
Moxonidine |
T6N CNJ B1 DO1 FG ENU- BT5MYMTJ |
MFCD06795643 |